Skip to main content

Catalyst Calendar

Mon, Sep 28, 2026

1 updates

4:00 PM

Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)

tevapharm.com

Wed, Sep 23, 2026

2 updates

4:45 PM

Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET

tevapharm.com

4:45 PM

Teva Releases Q3 2026 Aide Memoire

tevapharm.com

Fri, Sep 18, 2026

3 updates

4:32 PM

New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients

tevapharm.com

4:31 PM

Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs

tevapharm.com

4:30 PM

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

tevapharm.com

Wed, Sep 16, 2026

1 updates

8:00 AM

Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care

tevapharm.com

Mon, Sep 14, 2026

1 updates

8:03 AM

Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy

tevapharm.com

Thu, Sep 10, 2026

1 updates

6:04 AM

Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes

tevapharm.com

Mon, Sep 7, 2026

1 updates

3:53 AM

Teva Announces Launch of Offering of Senior Notes

tevapharm.com

Fri, Sep 4, 2026

1 updates

11:30 AM

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

tevapharm.com

Wed, Sep 2, 2026

1 updates

7:03 AM

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

Trial Results • Phase 2tevapharm.com

Tue, Sep 1, 2026

1 updates

4:30 PM

Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September

tevapharm.com

Mon, Aug 31, 2026

1 updates

4:06 PM

Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.

tevapharm.com

Fri, Aug 28, 2026

1 updates

6:17 AM

Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy

tevapharm.com

Tue, Aug 11, 2026

1 updates

8:00 AM

Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy

tevapharm.com

Wed, Jul 29, 2026

1 updates

7:00 AM

Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy

tevapharm.com